Shares of Coherus BioSciences Inc. (NASDAQ:CHRS) saw strong trading volume on Friday . 378,018 shares changed hands during mid-day trading, an increase of 9% from the previous session’s volume of 347,251 shares.The stock last traded at $17.22 and had previously closed at $16.43.

Separately, Zacks Investment Research downgraded Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 3rd.

The firm’s market capitalization is $674.01 million. The stock’s 50-day moving average price is $17.01 and its 200-day moving average price is $17.84.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Monday, May 9th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.42) by $0.25. On average, equities analysts expect that Coherus BioSciences Inc. will post ($5.90) earnings per share for the current year.

In other Coherus BioSciences news, insider Peter K. Watler sold 12,000 shares of the stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $20.00, for a total transaction of $240,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Alan C. Herman sold 4,250 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $19.20, for a total value of $81,600.00. Following the transaction, the insider now owns 207,167 shares in the company, valued at approximately $3,977,606.40. The disclosure for this sale can be found here.

A number of institutional investors have modified their holdings of CHRS. Jennison Associates LLC increased its position in shares of Coherus BioSciences by 3.1% in the fourth quarter. Jennison Associates LLC now owns 367,021 shares of the company’s stock worth $8,427,000 after buying an additional 11,023 shares in the last quarter. Brown Advisory Inc. boosted its position in shares of Coherus BioSciences by 3.0% in the fourth quarter. Brown Advisory Inc. now owns 200,918 shares of the company’s stock worth $4,614,000 after buying an additional 5,937 shares during the last quarter. CAM Group Holding A S boosted its position in shares of Coherus BioSciences by 17.7% in the fourth quarter. CAM Group Holding A S now owns 146,000 shares of the company’s stock worth $3,352,000 after buying an additional 22,000 shares during the last quarter. Finally, Columbus Circle Investors boosted its position in shares of Coherus BioSciences by 33.0% in the fourth quarter. Columbus Circle Investors now owns 276,752 shares of the company’s stock worth $6,354,000 after buying an additional 68,666 shares during the last quarter.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.